International Journal of Clinical Research

Objective To analyze the value of Montelukast Sodium as an adjuvant therapy for pediatric bronchiolitis. Methods Children with bronchiolitis admitted to the outpatient department of Jilin Peoples Hospital during a two-year period (sample inclusion time: October 2022~October 2024; sample inclusion number: 86 cases) were selected as the research subjects. Random grouping was used as the grouping principle, and they were divided into a control group (children assigned to this group received budesonide, n=43) and an experimental group (children assigned to this group received montelukast sodium treatment, n=43). Compare the therapeutic effects and inflammatory indicators between the two groups. Results In terms of clinical efficacy, the experimental group was higher than the control group (P<0.05). In terms of white blood cell count and C-reactive protein, the experimental group was lower than the control group (P<0.05). Conclusion Montelukast sodium has a definite effect as an adjuvant therapy for pediatric bronchiolitis, helping to reduce pulmonary inflammatory reactions, and can be further promoted and applied in clinical practice.

Pediatric bronchiolitis; Montelukast Sodium; Therapeutic effect; Inflammatory indicators